Core Insights - Calidi Biotherapeutics is hosting a webinar on November 19, 2025, to discuss its innovative approach to precision genetic medicine using the RedTail platform [1][2] - The RedTail platform is designed to deliver genetic medicines to metastatic tumor sites while avoiding immune detection, showcasing promising preclinical data [2][3] - The oncology market is projected to exceed $560 billion by 2033, presenting significant growth opportunities for Calidi [3] Company Overview - Calidi Biotherapeutics is a clinical-stage biotechnology company focused on developing targeted therapies for delivering genetic medicines to distal disease sites [1][6] - The proprietary RedTail platform utilizes an engineered enveloped oncolytic virus for systemic delivery, aiming to effectively reach tumor sites and induce tumor lysis [6][7] - The lead candidate from the RedTail platform targets non-small cell lung cancer, ovarian cancer, and other high unmet medical need tumor types [7] Financial Position - The third quarter 2025 earnings report indicated a strengthened balance sheet with reduced debt and an increased cash balance, alongside a decrease in general and administrative spending [3]

Group 1 - Compugen Ltd. (NASDAQ: CGEN) is an immuno-oncology biotech utilizing its Unigen platform for discovering immune checkpoints, drug candidates, and biomarkers [1] - The Unigen platform is based on Artificial Intelligence and Machine Learning technologies [1] Group 2 - The article does not provide any financial performance data or specific investment recommendations related to Compugen Ltd. [2][3]

Core Insights - Calidi Biotherapeutics Inc. is a clinical-stage biotechnology company focused on developing systemic oncolytic targeted immunotherapies, with its lead candidate CLD-401 presented at the ASCO Annual Meeting [1][2] Group 1: Technology and Innovation - Calidi has developed an enveloped form of its proprietary oncolytic virus that shows greater resistance to immune clearance, enhancing systemic delivery and efficacy in pre-clinical models [2] - The novel genetic modification in CLD-401 incorporates a chimeric CD55 receptor into the virus envelope, which inhibits complement-mediated clearance, improving the virus's stability in circulation [2][4] - The RedTail platform allows for the delivery of genetic payloads directly into the tumor microenvironment, with CLD-401 expressing an IL-15 superagonist to activate and expand natural killer (NK) cells and CD8+ T cells [3][4] Group 2: Strategic Development - Calidi is conducting IND-enabling studies for CLD-401 and plans to submit an Investigational New Drug (IND) application in the second half of 2026 [4] - The company is actively seeking strategic partnerships to accelerate clinical development and enhance the impact of its RedTail platform [4][6] - The lead candidate targets non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical needs [7]

Group 1: Phio Pharmaceuticals Corp. - Phio Pharmaceuticals Corp. is an immuno-oncology biotech company with a Zacks Rank 1 [1] - The Zacks Consensus Estimate for its current year earnings has increased by 14.4% over the last 60 days [1] - The company has a price-to-earnings ratio (P/E) of 0.66, significantly lower than the industry average of 7.20 [2] Group 2: Transportadora de Gas del Sur S.A. - Transportadora de Gas del Sur S.A. is a midstream energy company with a Zacks Rank 1 [2] - The Zacks Consensus Estimate for its current year earnings has increased by 4.6% over the last 60 days [2] - The company has a price-to-earnings ratio (P/E) of 19.11, which is comparable to the S&P average of 19.13 [3]

As filed with the Securities and Exchange Commission on January 16, 2024. Registration No. 333-274885 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Calidi Biotherapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 86-2967193 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identifi ...